The difference in market capital between MSB and CYP is largely due to the different stages that both companies are currently at:
- MSB has product on market, is about to launch a product in the US market and has multiple phase 3 trial readouts due by end of year and also has multiple licencing agreements with multiple pharmaceutical companies. MSB also has $180m cash on hand and
-CYP has no products on the market, only has one phase 3 trial which is yet to commence (currently on hold due to covid), and 3 products ready to enter phase 2 trials as well as an agreement with Fujifilm for $2.86m upon completion of planned phase 2 trial and a potential $43m in milestone and licencing payments. CYP has $13.6m cash on hand.
CYP has huge potential just like MSB, however has a long way to go before any commercialisation can begin. CYP represents a higher risk to investors due to phase 2 and 3 trials that are yet to begin and the longer path to commercialisation, probably at least 18 months before any potential product can be launched.
- Forums
- ASX - By Stock
- MSB
- New video discussion with Mesoblast CEO
New video discussion with Mesoblast CEO, page-90
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 97.0¢ | $2.821M | 2.832M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20688 | 97.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 35000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20688 | 0.975 |
6 | 137742 | 0.970 |
6 | 111862 | 0.965 |
5 | 79094 | 0.960 |
1 | 5200 | 0.955 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 35000 | 3 |
0.995 | 69662 | 5 |
1.000 | 33108 | 4 |
1.005 | 20000 | 1 |
1.010 | 73320 | 2 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online